Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations
- PMID: 33170973
- DOI: 10.1002/hep.31618
Letter to the Editor: Using Circulating Biomarkers to Stage HCC: Pitfalls and Limitations
Comment in
-
REPLY.Hepatology. 2021 Jun;73(6):2612. doi: 10.1002/hep.31620. Epub 2021 May 24. Hepatology. 2021. PMID: 33170975 No abstract available.
Comment on
-
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk.Hepatology. 2021 Jun;73(6):2278-2292. doi: 10.1002/hep.31555. Epub 2021 Jun 15. Hepatology. 2021. PMID: 32931023 Free PMC article.
References
-
- Morris JS, Hassan MM, Zohner YE, Wang Z, Xiao L, Rashid A, et al. HepatoScore-14: measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk. Hepatology 2020 Sep 15. https://doi.org/10.1002/hep.31555. [Epub ahead of print]
-
- Liu P-H, Hsu C-Y, Hsia C-Y, Lee Y-H, Huang Y-H, Su C-W, et al. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. Eur J Cancer 2016;63:25-33.
-
- Liu P-H, Hsu C-Y, Hsia C-Y, Lee Y-H, Su C-W, Huang Y-H, et al. Prognosis of hepatocellular carcinoma: assessment of eleven staging systems. J Hepatol 2016;64:601-608.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical

